<qa>  How many patients will receive infliximab or adalimumaPatients This multicentre prospective cohort study will be conducted at three sites in Nottingham Nottingham University Hospitals, London Northwick Park NHS Foundation Trust and Manchester Salford Royal NHS Foundation Trust. A total of 20 patients age 16-75 years with pCD as deemed by a PDAI of 4 and a clinician assessment, prior to the onset of biological therapy. All eligible patients will receive infliximab or adalimumab or Ustekinumab. Patients will have infliximab 5 mgkg i.v. at weeks 0, 2, 6 and 8 weekly thereafter, or Adalimumab subcutaneously s.c. at week 0 160 mg, 2 80mg, 40 mg every 2 weeks thereafter or Ustekinumab 6mgkg i.v. at week 0 and a weight-based s.c. every 12 weeks thereafter. Patients will be excluded from the study if they are due to have surgery in the near future 12 weeks. 